Cambria Investment Management L.P. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 255.2% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned
Stock News Fed set to ease bank capital rules: The Federal Reserve is poised to cut capital requirements by about 4.8% for the largest lenders, a move that coul
Eli Lilly has strong momentum thanks to its leadership in the weight loss market. Vertex Pharmaceuticals' core franchise and newer approvals could drive top-line growth for a long time.
Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug low
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%)
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Roche Holding AG has announced a major AI infrastructure expansion with Nvidia, surpassing peers in GPU deployment for drug development. RHHBY now operates over 3,500 Blackwell GPUs, positioning itsel

Stock Of The Day: Is The Eli Lilly Selloff Over?

01:30pm, Wednesday, 18'th Mar 2026
As you can see on the chart, in April 2025 when Eli Lilly reached the $890 level, it hit resistance. A reversal and move lower followed.
Lawmakers on both sides of the aisle have recently proposed banning members of Congress from trading individual stocks while in office. This sentiment dates back to the STOCK Act of 2012, which was su
Coldstream Capital Management Inc. raised its position in Eli Lilly and Company (NYSE: LLY) by 25.6% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 42,418 s
Caitong International Asset Management Co. Ltd bought a new position in shares of Eli Lilly and Company (NYSE: LLY) in the undefined quarter, according to the company in its most recent Form 13F filin
Cim Investment Management Inc. trimmed its holdings in Eli Lilly and Company (NYSE: LLY) by 50.6% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor
Advisory Services Network LLC raised its position in shares of Eli Lilly and Company (NYSE: LLY) by 4.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange
Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong.
Hims & Hers' stock is up after ending its lawsuit with Novo Nordisk. The deal shows that industry power lies with the drugmakers.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE